the for Good Ilan you, Thank introduction. afternoon.
on On Let I'm today's up I a to significant welcome Carl call, to call. me bringing extend date Chief XXXX. will this on you Financial everyone shareholder be transactions Officer. in Iberger, Precipio's completed
Our obtain operations. and operating breakeven balance we to to need accomplish what performance sheet and our
a us taken on benefit will financial and concluded with either during Let my has been company negative drain significant several our to-date. items When and future. they company the have material these considering individually QX. addressing resource these me or behind the collectively, discussion items start Getting
reported been these in items on of have our All XX-Q.
company past claims Transgenomic significant had it. entered from the as this both end XXXX two First, Precipio XXXX legal related the Both company matters. the holdovers merger. pre-merger the settled facing By were of quarter, investor
on claim first Transgenomic. is Crede matter Capital The
has the and matter dating this XXXX, been material fully off weight with XXXX financial May Crede the obligations is of Transgenomic settling to concluding liability inherited paid its of lifted origin Capital As settled July company. to and a back
documents a on activities et pre-merger. from a our financials. is In been quarter parties Transgenomic impact second stemming have The All of QX. settlement legal settlement. Campbell negotiations All al. accounted a June, will for be agreed is during action the Transgenomic completed in second have were completed. lawsuit. Final matter
but by year. also At vendors. with The release and outstanding in also non-legal LLC. all to Leviston dealing conclusion with settled, item of more has three do legacy was item agreement Leviston Precipio contractual completed settlements the related has with QX, Precipio and has with third fully satisfied item, was this merger and settlement. Resources accounts This post-merger payable counterclaims signed June, of completed May executed major and obligations during fourth remaining claims a A
With the page turn company the finally these settlements, legacy can on payables. the
adjusted we outlays of stock stock the worked debt and years, split an $X the During April of this and XX, to two the shareholder executed company million the last remain previous on in call on million. The through reverse in press reverse has cash in in company million provided minimizing The XX action. possibly exchange. order information been June QX the settlement addressed Also the for financial of to split XX Q NASDAQ as outstanding negotiations, releases, shares, In legacy Ilan has a approximately and May, incorporate X.X off XXXX. XX. X claims excess
The management to footnotes operating disclosure, XXQ on financials, business filed our activities. Moving reporting company to our and X, I'd performance, our exhibits it's like August address discussion legal analysis.
XXth. six month quarter the During revenues ending for grew period, over Total the this and over covering reported six period year period and reporting XX% June month quarter three X% year. of
services taking annualized pathology continue testing on the rate this we Of the services rate the diagnostic the XX%. pharma believe exceeding our approximately period, amount as account for back second XX%. to our revenues. for of provides reported and Pharma all annualized in half, services a look our at of will projections revenue. represent remaining additional this growth current growth Stepping of contracts Based increase, reporting all of almost XX% from
its August. pathology New license lab [indiscernible] in Connecticut Our cap approval received recently Haven,
securing practices. In our with Miller, expanding additional key directly force. believe in diagnostic cap led sales we related will Growth that by sales Steve to into from recent oncology translate team certificate sales our pathology conversations is the
the from built this During the pharmaceutical balance. have pharma XX force relationships comes of The office revenues the quality the is our expansion, cover multi-oncologist projects. to physician services account and first revenues developers. revenue and the centers our generated comprised is companies, diagnostic contracts clinical we These Paramount half pathology revenue. hospitals force to states. steadily house make in comprise direct sales oncologists of approximately through and sales down remaining for contract and/or now These up assigned reported research from success a projects with based physician patient and testing from generate of XXXX, Breaking customer doc majority testing XX% cases. Medical increased profiles, groups. team we
Our pharma facility. the by provided research company's Omaha, services Nebraska are
of the laboratories economies time we their needs, revenues, are technical currently late will we are not requirements placed, being and capacity the IV-cell for Currently, expand affording throughout most overall touched leverage cytogenetic XXXX previously, these for HemeScreen testing noted the to developed management scale. have will improved volume our only lab team clinical application. and reference demonstrated volume. two reducing to processes When and ability and as and new marketed about launched XXXX. IV-cell lab media is and take in to on its help recently, confident own processes, providing expenses, the U.S., Ilan Asia laboratory us upon, QX, Brazil. the HemeScreen supplant has extremely As results, and lab molecular significant have orders Internally staff The costs. technology hospitals existing launching Both increased products saving but
turnaround outcomes have as new and New our to processes services Haven, well expand Connecticut to clinical improved it's These pathology lab markedly offer as lab improved time. allowed
with external not all labs very has disappointed time to We we the it However, in remain validation of taken encouraged we're testing. complete satisfied. said, length that but are
edge confident can We we are to valuation. all closer and doing completion we're external
significant We as to the a but seen margins by sales and increases. generated project continuing proven gross to we've or volume markedly only margins, volume. improvement margin gross be Gross can build improved
operating to SG&A. and Moving expenses
result force. level made on the in been curtailed, have and G&A while have not material sales These essentially the expenses year material of and expenses half. of changes over in reinvested for grown expenses are discussed year our support. obvious finalizing Legal operate shall are in reporting reductions to savings are the public certain is legal. size to we What that Legal IT progress previously G&A have has required expenses XX%. we the reducing our Our expenses, are been Key sales second direct business focused by auditing settlements. see have a is cost in as expense. We X% the G&A significantly
Going forward, continue to to need we reduce expenses.
associated expenses, and expenses expense public specifically our item financial accounting valuation for from noted, public technical expenses from reporting services to analysis size fees in. states financial provide they're reporting NASDAQ, business. today, and the single largest that and Multiple our related business public Precipio to Stepping and comprised reporting Delaware well that on accounting of the As instruments. corporate instruments, from by taxes back driven audit for guidance through as accounting we for franchise incorporating reporting of our our
our Taken as are excessive a company. costs whole, for public reporting
While and remainder invest we to the the business. building making XXXX, throughout tools are force progress we G&A grow into all or expense on expenses sales repurpose expanding reporting the reductions customer will
of Looking I forward, their these by financials volume. second as way the believe force drives the expansion, will half proof efforts sales to find G&A reductions funded
to modifications evaluation resulted during material the quarter and instruments and last our expenses warrant notes. financial activity derivative expenses related along other initial and price income was Moving and the to sub-convertible it and that in
and -- ended million, months million the well of XXXX XX, of X.X expense a million derivative warrant revaluation of as for from million was three net expenses especially. ended convertible of other included same for million of months and X.X XX-Q June revaluations billion issuance X.X the loss in six identified and and warrant X.X and income and the X.X from X.X notes XXXX as As of and derivative period
of months expense other gains by XX, will settlement items offset million partially the ended XXXX of three During X.X and June liabilities
for our looking million, to June reserves XX, the was cash XX/XX/XX. activities, and the DSO year to reflected revenues, at sheet the to at previously as company XX. and operations liabilities receivable proportionate assets, balance XX, cash of Accounts increase clear our at XXXX of fund in No flow X.X DSO favorable discussed settlements. as XX/XX million XXXX, were in June X.X compared year-end Moving and XX
new million also of During received the and quarter million from the X.X in issued of proceeds ending June XXth warrants. the company exercise debt, X.X
of statements payable year million liabilities operations. liability expenses million recently million decrease XX, a or [ph] reflected for the related ending X.X for compared AP of million. to cumulative use accounts gain of a amounts X.X X.X XXXX, and of our approximately concluded As June to in of accrued X.X a Changes of as XX/XX negotiated in proceeds making payment and
cash line FX company successfully and existing are provide cash reach The HemeScreen company the filed X.X flow believes August reserves, proceeds million. equity and for estimated company with should market to Recently, on breakeven sufficient profitability. an proceeds the and combined Xth, runway the IV-cell
final back some me let Now, it for turn to Ilan comments.
